SUBSCRIBE
SUBSCRIBE
News   Drug Development

Dicerna Reports First Quarter 2016 Financial and Operational Results

May 10, 2016 | 
1 min read
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.

Clinical research Phase 1 Phase 2 Earnings
MORE ON THIS TOPIC
Hand Marking Calendar Reminder Illustration. A professional hand uses a pen to circle a date on a red and white calendar, representing schedule planning and important reminders
FDA
Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
August 24, 2026
 · 
2 min read
 · 
Heather McKenzie
Row of Falling Domino Stones Stopped by Red Domino Stone Over Black Background, Risk Management, Intervene or Prevention Concept, 3d Rendering
FDA
REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans
August 24, 2026
 · 
2 min read
 · 
Heather McKenzie
Time on the hourglass stopped. Clock on table. Pause in business, collapse.
Pipeline
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
August 24, 2026
 · 
1 min read
 · 
Tristan Manalac
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Duchenne muscular dystrophy
Capricor investor calls for change as company awaits decision on Duchenne candidate
August 21, 2026
 · 
3 min read
 · 
Heather McKenzie